CHNA
Loncar China BioPharma ETF
CHNA
CHNA
Delisted
CHNA was delisted on the 20th of October, 2023.
4 hedge funds and large institutions have $920K invested in Loncar China BioPharma ETF in 2021 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
4
Holders Change
-3
Holders Change %
-42.86%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
1 |
UBS Group
Zurich,
Switzerland
|
+$47.6K |
2 |
Morgan Stanley
New York
|
+$6.96K |
3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$4K |
Top Sellers
1 |
Jane Street
New York
|
-$753K |
2 |
Citadel Advisors
Miami,
Florida
|
-$346K |
3 |
FEM
Fulcrum Equity Management
Plano,
Texas
|
-$326K |
4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$23K |